2 days Ago By Defense World Staff
Commonwealth Equity Services LLC purchased a new position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 44,500 shares of the company’s stock, valued at approximately $64,000.
Commonwealth Equity Services LLC owned about 0.06% of Tenaya Therapeutics as of its most recent filing with the Securities & Exchange Commission. A number of other institutional investors and hedge funds also recently modified their holdings of the stock.
Synovus Financial Corp acquired a new position in Tenaya Therapeutics in the 3rd quarter worth approximately $28,000. Spire Wealth Management acquired a new stake in shares of Tenaya Therapeutics in the fourth quarter worth $53,000. SG Americas Securities LLC grew its position in shares of Tenaya Therapeutics by 61.
9% in the fourth quarter. SG Americas Securities LLC now owns 41,270 shares of the company’s stock valued at $59,000 after purchasing an additional 15,777 shares during the last quarter. Atticus Wealth Management LLC increased its position in Tenaya Therapeutics by 56.
3% in the 4th quarter. Atticus Wealth Management LLC now owns 47,762 shares of the company’s stock worth $68,000 after buying an additional 17,199 shares during the period. Finally, XTX Topco Ltd increased its holdings in shares of Tenaya Therapeutics by 51.
2% during the 3rd quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock worth $95,000 after purchasing an additional 16,687 shares during the period. 90.
54% of the stock is owned by institutional investors and hedge funds. Insider ActivityIn other news, major shareholder Group Gp Lp Column III acquired 35,714,284 shares of the stock in a transaction dated Wednesday, March 5th. The shares were bought at an average cost of $0.
70 per share, for a total transaction of $24,999,998.80. Following the purchase, the insider now directly owns 49,313,559 shares of the company’s stock, valued at approximately $34,519,491.
30. This trade represents a 262.62 % increase in their ownership of the stock.
The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 19,621 shares of company stock worth $10,595 in the last quarter. Corporate insiders own 32.
76% of the company’s stock. Tenaya Therapeutics Price PerformanceNASDAQ TNYA opened at $0.49 on Friday.
Tenaya Therapeutics, Inc. has a one year low of $0.39 and a one year high of $4.
96. The stock’s 50-day moving average is $0.74 and its 200-day moving average is $1.
56. The firm has a market cap of $43.17 million, a P/E ratio of -0.
34 and a beta of 2.98. Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) last posted its quarterly earnings data on Monday, March 17th.
The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.
04. Equities analysts anticipate that Tenaya Therapeutics, Inc. will post -1.
35 EPS for the current year. Analyst Upgrades and DowngradesA number of research firms have weighed in on TNYA. HC Wainwright reiterated a “buy” rating and set a $5.
00 price target on shares of Tenaya Therapeutics in a research note on Monday, March 31st. Chardan Capital decreased their price objective on shares of Tenaya Therapeutics from $18.00 to $9.
00 and set a “buy” rating on the stock in a report on Wednesday, March 12th. Morgan Stanley cut their price target on Tenaya Therapeutics from $15.00 to $5.
00 and set an “overweight” rating on the stock in a research note on Wednesday, March 12th. Finally, Canaccord Genuity Group lowered their target price on shares of Tenaya Therapeutics from $18.00 to $6.
00 and set a “buy” rating for the company in a report on Thursday, March 13th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $6.
25.View Our Latest Stock Analysis on TNYATenaya Therapeutics Profile (Free Report)Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition.
The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.Featured StoriesFive stocks we like better than Tenaya TherapeuticsHow to Know if a Stock Pays Dividends and When They Are Paid OutJPMorgan is a Buy, if You Can Handle The Volatility What is a Special Dividend?United States Steel’s Crash: An Unmissable Buying OpportunityInvesting in Construction StocksRocket Lab Stock: Weathering the Storm, Time for a Comeback?Want to see what other hedge funds are holding TNYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tenaya Therapeutics, Inc.
(NASDAQ:TNYA – Free Report)..
